A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

876

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

July 1, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

SHR-1826

DRUG

SHR-4642

DRUG

SHR-9839

DRUG

SHR-8068

DRUG

Bevacizumab Injection

DRUG

Fluorouracil Injection

DRUG

Calcium Folinate Injection

DRUG

Adebrelimab Injection

Trial Locations (1)

RECRUITING

Sun Yat-Sen university cancer center, Guangzhou

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY